For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 24,903 | |||
| General and administrative | 12,811 | |||
| Total operating expenses | 37,714 | |||
| Loss from operations | -37,714 | |||
| Change in fair value of warrant liabilities | 1,915 | |||
| Loss on issuance of pre-funded warrants | 0 | |||
| Gain on sale of equipment | 0 | |||
| Foreign exchange transaction gain | 0 | |||
| Grant income | 415 | |||
| Interest income | 776 | |||
| Interest expense | 1,133 | |||
| Total other expense, net | -1,857 | |||
| Us federal statutory income tax rate | -8,310 | |||
| Domestic state and local taxes, net of federal effect | 0 | |||
| Foreign tax effects | 20 | |||
| Research and development credits | 1,126 | |||
| Nondeductible stock based compensation | 310 | |||
| Change in fair value of warrants | 402 | |||
| Other nontaxable and nondeductible items | 244 | |||
| Changes in valuation allowance | 8,460 | |||
| Provision for income taxes | 0 | |||
| Net loss | -39,571 | |||
| Foreign currency translation adjustment | 48 | |||
| Comprehensive loss | -39,523 | |||
| Basic EPS | -2.58 | |||
| Diluted EPS | -2.58 | |||
| Basic Average Shares | 15,312,751 | |||
| Diluted Average Shares | 15,312,751 | |||
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)